arrow
W

Wen-Chien Chou

National Taiwan University Hospital
H指数:50
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early post-transplant molecular residual disease predicts outcomes in myelodysplastic neoplasms/syndromes and acute myeloid leukemia undergoing allogeneic transplantation

移植早期分子残留病灶可预测接受异基因移植的骨髓增生异常肿瘤/综合征和急性髓系白血病的结局

2026-10-010
OAAI
An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter Study

免疫功能障碍特征评分可预测MDS患者的生存:来自一项纵向、多中心研究的见解

2026-04-280
OA
Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data

高强度治疗急性髓系白血病中伴随发生的FLT3突变在分子亚组间的预后影响:来自真实世界基因组数据的见解

2026-01-060
OAAI
Diagnostic utility and pitfalls of human T-lymphotropic virus serology in adult T-cell leukemia/lymphoma: evidence from a 25-year pathology-based nonendemic cohort

成人T淋巴细胞白血病/淋巴瘤中人类T淋巴细胞病毒血清学的诊断效用和陷阱: 来自25年基于病理学的非地方性队列的证据

2025-12-290
OAAI
Genomic and transcriptomic characterization of acute myeloid leukaemia with IL3RA overexpression: Prognostic and therapeutic implications revisited

IL3RA过表达急性髓系白血病的基因组与转录组特征:预后和治疗意义再探讨

2025-11-180
PRE
Consensus of the Hematology Society of Taiwan on the management of paroxysmal nocturnal hemoglobinuria (PNH)

中华血液学会关于阵发性睡眠性血红蛋白尿症(PNH)管理的共识

2025-10-280
OAAI
Molecular Milestones and Survival Outcomes of Ponatinib Treatment in Patients With Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Real-World Analysis

分子里程碑与生存结局:Ponatinib治疗慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病的真实世界分析

2025-09-020
PRE
INCORPORATING TET2 VARIANT ALLELE FREQUENCY ENHANCES PROGNOSTICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA: A MULTICENTER STUDY

纳入TET2变异等位基因频率可增强慢性粒单细胞白血病的预后评估:一项多中心研究

2025-09-010
PRE
Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study

真实世界证据:罗培干扰素α-2b在骨髓增殖性肿瘤患者中的疗效与安全性研究:一项回顾性队列研究

2025-06-250
PRE
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations

AML和DNMT3A突变患者临床结局的基因组学和转录组学决定因素

2025-05-200
OA